Table 2 Odds ratios (ORs) and 95% confidential intervals (CIs) for pCR in all patients.

From: Prognostic value of neutrophil-to-lymphocyte ratio in human epidermal growth factor receptor 2-negative breast cancer patients who received neoadjuvant chemotherapy

 

Univariate

Multivariate

OR (95% CIs)

P-value

OR (95% CIs)

P-value

Age

0.996 (0.982–1.011)

0.62

0.992 (0.977–1.008)

0.336

NLR

< 2.74

Ref

 

Ref

 

≥ 2.74

0.680 (0.476–0.971)

0.034

0.595 (0.398–0.890)

0.011

cT stage

 

0.002

 

< 0.001

1

Ref

 

Ref

 

2

1.320 (0.856–2.036)

0.209

0.804 (0.489–1.324)

0.392

3

0.596 (0.336–1.056)

0.076

0.327 (0.172–0.621)

0.001

cN stage

Negative

Ref

 

Ref

 

Positive

0.407 (0.285–0.582)

< 0.001

0.583 (0.385–0.883)

0.011

ER

Positive

Ref

 

Ref

 

Negative

7.713 (5.462–10.892)

< 0.001

5.017 (3.033–8.299)

< 0.001

PR

Positive

Ref

 

Ref

 

Negative

7.515 (5.034–11.220)

< 0.001

2.283 (1.289–4.044)

0.005

Regimen

 

0.002

 

< 0.001

AC-T

Ref

 

Ref

 

AC

0.516 (0.198–1.345)

0.176

0.407 (0.142–1.168)

0.095

AT

0.381 (0.225–0.644)

< 0.001

0.308 (0.174–0.544)

< 0.001

Others*

0.941 (0.457–1.939)

0.870

0.741 (0.333–1.651)

0.463

  1. pCR pathologic complete response, NLR neutrophil to lymphocyte ratio, cT clinical T stage, cN clinical N stage, ER estrogen receptor, PR progesterone receptor, AC-T doxorubicin and cyclophosphamide followed by taxane, AC doxorubicin and cyclophosphamide, AT doxorubicin and taxane.
  2. *Others: cyclophosphamide, doxorubicin, 5-fluorouracil (CAF); cyclophosphamide, methotrexate, 5-fluorouracil (CMF); taxane; taxane plus carboplatin.
Back to article page